Evan Jones, Chairman and CEO
Mr. Jones is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute. Mr. Jones is Chairman of the Board for the Campaign for Public Health, an organization dedicated to making public health and prevention a higher national priority. He serves on the Board of Directors of Research!America. He has a BA degree from the University of Colorado and an MBA from The Wharton School, University of Pennsylvania.
Eric Winzer, CFO
Eric joined OpGen as Chief Financial Officer in June 2009. Eric brings almost 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Eric is responsible for all financial functions at the Company.
Prior to joining Opgen, Eric served as Executive Vice President and Chief Financial Officer for Avalon Pharmaceuticals, Inc., a biotechnology company developing targeted therapeutics for oncology. Prior to Avalon, Eric was with Life Technologies Corporation (formerly Invitrogen Corporation), a provider of life science technologies for disease research and drug discovery, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life’s ERP implementation, and as the VP of Finance. Previously held positions also include Eric’s tenure at Life Technologies Incorporated, where he assumed increasing responsibility as Chief Financial Officer, Secretary and Treasurer, and additionally held various financial positions at Genex Corporation. Currently, Eric serves as director and audit committee chair at Cytomedix, Inc.
Eric received his B.A. in Economics and Business Administration from McDaniel College and an M.B.A. from Mount Saint Mary’s University.
Tom Ross, Sr. VP, Commercial Operations
Tom has extensive experience in all elements of commercial operations and has over 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently Tom served as Chief Commercial Officer at Predictive BioSciences, a molecular diagnostics laboratory with a focus on Bladder and Prostate cancer. Prior to Predictive BioSciences, he was the Vice President of North America Medical Diagnostics Sales at QIAGEN/Digene Corporation. Prior to Digene, Tom held several senior leadership roles at Life Technologies and Cambrex. In addition to his sales and marketing experience, Tom held management positions in Manufacturing Operations at Life Technologies and Cambrex.
Tom has a B.S in Business Administration from The Citadel.
Vadim Sapiro, CIO
Vadim joined OpGen in December, 2011 with responsibility for leading the development of the Company’s bioinformatics applications, software, databases and information technology operations. Prior to OpGen Mr. Sapiro was senior vice president at SAIC-Frederick overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among Mr. Sapiro’s projects were technical program management and operations for the cancer Biomedical Informatics Grid (caBIG™), the cancer Human Biobank (caHUB) and The Cancer Genome Atlas (TCGA). Prior to SAIC, Mr. Sapiro was vice president for information technology with the J. Craig Venter Institute. Mr. Sapiro is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees.
Mr. Sapiro holds a B.S. in mathematics and computer science from the University of Maryland.